As of this writing, brand-name Saxenda and Victoza are listed on the FDA drug-shortage list, which allows certain pharmacies to compound liraglutide in accordance with federal and state regulations
Nearly 86% of the semaglutide group lost at least 5% of body weight, and 69% lost at least 10% [1]
Key appetite-related changes patients typically experience include: Reduced hunger between meals Earlier onset of fullness during eating Decreased food cravings, particularly for high-fat or high-sugar foods Reduced interest in eating overall These combined effects create a powerful tool for weight management but require careful monitoring, as excessive appetite suppression can lead to inadequate nutrition or dehydration if patients struggle to meet basic caloric and fluid needs
It is a naturally occurring antioxidant valued for its health benefits
PEAs documented anti-inflammatory, analgesic, antimicrobial, immunomodulatory, and neuroprotective effects make it a versatile ingredient with broad therapeutic applications
